Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec:72 Pt A:104-16.
doi: 10.1016/j.nbd.2014.05.019. Epub 2014 May 27.

Nuclear receptors in neurodegenerative diseases

Affiliations
Review

Nuclear receptors in neurodegenerative diseases

Rebecca Skerrett et al. Neurobiol Dis. 2014 Dec.

Abstract

Nuclear receptors have generated substantial interest in the past decade as potential therapeutic targets for the treatment of neurodegenerative disorders. Despite years of effort, effective treatments for progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and ALS remain elusive, making non-classical drug targets such as nuclear receptors an attractive alternative. A substantial literature in mouse models of disease and several clinical trials have investigated the role of nuclear receptors in various neurodegenerative disorders, most prominently AD. These studies have met with mixed results, yet the majority of studies in mouse models report positive outcomes. The mechanisms by which nuclear receptor agonists affect disease pathology remain unclear. Deciphering the complex signaling underlying nuclear receptor action in neurodegenerative diseases is essential for understanding this variability in preclinical studies, and for the successful translation of nuclear receptor agonists into clinical therapies.

Keywords: Alzheimer's disease; Amyotrophic lateral sclerosis; Huntington's disease; Inflammation; Liver X receptors; Microglia; Neurodegeneration; Nuclear receptors; Parkinson's disease; Peroxisome proliferator-activated receptors; Retinoid X receptors.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Nuclear receptors are ligand-activated transcription factors
Nuclear receptors (type II) form obligate heterodimers with RXR and comprise the functional transcription factor. The nuclear receptor complex transactivates its target genes by binding to sequence specific elements in their promoters. Ligand binding results in dismissal of a corepressor complex and association with coactivators, resulting in transcription of the target gene. Nuclear receptors can also act as transrepressors. Sumoylation induces their direct association with NFkB positioned on the promoters of proinflammatory genes, preventing the dismissal of corepressor complexes and the initiation of transcription.

References

    1. A-Gonzalez N, et al. Apoptotic Cells Promote Their Own Clearance and Immune Tolerance through Activation of the Nuclear Receptor LXR. Immunity. 2009;31:245–258. - PMC - PubMed
    1. Akram A, Schmeidler J, Katsel P, Hof PR, Haroutunian V. Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis? Molecular Neurodegeneration. 2010;5:36. - PMC - PubMed
    1. Alaynick WA. Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion. 2008;8:329–337. - PMC - PubMed
    1. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nature Reviews Molecular Cell Biology. 2011;12:141–151. - PMC - PubMed
    1. Andersson S, Andersson R, Gustafsson N, Warner M, Gustafsson J. Inactivation of liver X receptor beta leads to adult-onset motor neuron degeneration in male mice. Proceedings of the National Academy of Sciences of the United States of America. 2005;102:3857–3862. - PMC - PubMed

MeSH terms

Substances